ProCE Banner Activity

CE / CME

The New Standard of Care: Leveraging the Benefits of SGLT2 Inhibitors Across the Heart Failure Spectrum

Video

Experts review key data on SGLT2 inhibitors across the spectrum of heart failure in this webinar recording from HFSA 2023. Learn about updated classifications and staging, key SGLT2i trials, and strategies to manage and mitigate adverse events when using SGLT2is.

Physician Assistants/Physician Associates: 1.25 AAPA Category 1 CME credits

Nurses: 1.25 Nursing contact hours

Physicians: maximum of 1.25 AMA PRA Category 1 Credits

Released: October 27, 2023

Expiration: October 26, 2024

No longer available for credit.

Share

Faculty

Javed Butler

Javed Butler, MD, MPH, MBA

President
Baylor Scott and White Research Institute
Dallas, Texas
Distinguished Professor of Medicine
Department of Medicine
University of Mississippi Medical Center
Jackson, Mississippi

Lee R. Goldberg

Lee R. Goldberg, MD, MPH, FACC, FAHA, FHFSA

Vice Chair of Medicine for Informatics
Section Chief, Advanced Heart Failure and Cardiac Transplant
Professor of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC in partnership with the Heart Failure Society of America

ProCE Banner

Supporters

This activity is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

Boehringer Ingelheim Pharmaceuticals, Inc.

Eli Lilly and Company

Target Audience

This program is intended for cardiologists (physicians and fellows), internists, primary care providers, nurse practitioners, physician associates/physician assistants, and other healthcare professionals who care for patients with heart failure.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with heart failure.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss the latest clinical trial evidence in support of the safety and efficacy of SGLT2 inhibition as key treatments for patients across the HF spectrum

  • Design and implement strategies that incorporate the SGLT2 inhibitor drug class as a key component of guideline-directed medical therapy for a wide range of patients with HF

  • Use the most recent real-world evidence and current clinical guidelines to initiate and optimize guideline-directed medical therapy for patients with HF

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Javed Butler, MD, MPH, MBA

President
Baylor Scott and White Research Institute
Dallas, Texas
Distinguished Professor of Medicine
Department of Medicine
University of Mississippi Medical Center
Jackson, Mississippi

Javed Butler, MD, MPH, MBA: consultant/advisor/speaker: Abbott, American Regent, Amgen, Applied Therapeutic, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardiac Dimension, Cardior, CVRx, Cytokinetics, Edwards, Element Science, Imbria, Impulse Dynamics, Innolife, Inventiva, Janssen, Lilly, LivaNova, Lexicon, Medtronics, Merck, Novartis, Novo Nordisk, Occlutech, Pfizer, Pharmacosmos, Roche, Sequana, SQ Innovation, Vifor.

Lee R. Goldberg, MD, MPH, FACC, FAHA, FHFSA

Vice Chair of Medicine for Informatics
Section Chief, Advanced Heart Failure and Cardiac Transplant
Professor of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Lee R. Goldberg, MD, MPH, FACC, FAHA, FHFSA: consultant/advisor/speaker: Abbott, Viscardia, Zoll/Respicardia.

The planners and content peer reviewers from Clinical Care Options, LLC and Heart Failure Society of America do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from October 27, 2023, through October 26, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

The program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

A logo for a companyDescription automatically generated with low confidence

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.25 contact hours.

Physician Associate Continuing Medical Education

AAPA

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until October 26, 2024 . PAs should only claim credit commensurate with the extent of their participation.